NASDAQ:KTTA Pasithea Therapeutics (KTTA) Stock Price, News & Analysis $1.91 -0.23 (-10.75%) Closing price 02/7/2025 04:00 PM EasternExtended Trading$1.80 -0.12 (-6.02%) As of 02/7/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends About Pasithea Therapeutics Stock (NASDAQ:KTTA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Pasithea Therapeutics alerts:Sign Up Key Stats Today's Range$1.83▼$2.1250-Day Range$1.91▼$3.1552-Week Range$1.83▼$9.25Volume494,845 shsAverage Volume3.17 million shsMarket Capitalization$2.43 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewPasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.Read More… Pasithea Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks26th Percentile Overall ScoreKTTA MarketRank™: Pasithea Therapeutics scored higher than 26% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Pasithea Therapeutics. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioPasithea Therapeutics has a P/B Ratio of 0.09. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Pasithea Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.00% of the float of Pasithea Therapeutics has been sold short.Short Interest Ratio / Days to CoverPasithea Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pasithea Therapeutics has recently decreased by 60.47%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPasithea Therapeutics does not currently pay a dividend.Dividend GrowthPasithea Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.00% of the float of Pasithea Therapeutics has been sold short.Short Interest Ratio / Days to CoverPasithea Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pasithea Therapeutics has recently decreased by 60.47%, indicating that investor sentiment is improving significantly. News and Social Media2.4 / 5News Sentiment0.38 News SentimentPasithea Therapeutics has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Pasithea Therapeutics this week, compared to 0 articles on an average week.Search Interest3 people have searched for KTTA on MarketBeat in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Pasithea Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders16.30% of the stock of Pasithea Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 23.92% of the stock of Pasithea Therapeutics is held by institutions.Read more about Pasithea Therapeutics' insider trading history. Receive KTTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pasithea Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address KTTA Stock News HeadlinesPasithea Therapeutics Shares Rise After Positive Safety Review for Cancer TreatmentFebruary 6 at 4:13 AM | marketwatch.comPasithea announces Safety Review Committee recommendationFebruary 6 at 4:13 AM | markets.businessinsider.comElon’s AI venture could 10X (here’s how you could profit)What does Elon plan with all this computing power? Our research indicates he's gunning to take over the entire AI industry - which is projected to grow up to $23 TRILLION annually in the coming years... Elon's AI venture is already growing 7X faster than its main competitor, OpenAI. It could soon be the most powerful AI firm on the planet.February 8, 2025 | Behind the Markets (Ad)Big Mid-Week Move From This Small BiotechFebruary 6 at 4:13 AM | msn.comPasithea's PAS-004 advances in cancer trial with no toxicitiesFebruary 6 at 4:13 AM | msn.comPasithea Therapeutics Advances PAS-004 Clinical Trial to Next Dose Level Following Safety Review Committee RecommendationFebruary 5 at 7:17 AM | quiverquant.comPasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced CancerFebruary 5 at 6:59 AM | globenewswire.comKTTA stock touches 52-week low at $2.19 amid market challengesJanuary 31, 2025 | msn.comSee More Headlines KTTA Stock Analysis - Frequently Asked Questions How have KTTA shares performed this year? Pasithea Therapeutics' stock was trading at $3.15 on January 1st, 2025. Since then, KTTA stock has decreased by 39.4% and is now trading at $1.91. View the best growth stocks for 2025 here. When did Pasithea Therapeutics' stock split? Shares of Pasithea Therapeutics reverse split on the morning of Tuesday, January 2nd 2024. The 1-20 reverse split was announced on Tuesday, January 2nd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Pasithea Therapeutics IPO? Pasithea Therapeutics (KTTA) raised $17 million in an IPO on Wednesday, September 15th 2021. The company issued 2,898,551 shares at a price of $5.00-$7.00 per share. How do I buy shares of Pasithea Therapeutics? Shares of KTTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Pasithea Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pasithea Therapeutics investors own include Biofrontera (BFRI), Meta Platforms (META), Plug Power (PLUG), QuantumScape (QS), Airbnb (ABNB), Advanced Micro Devices (AMD) and Ginkgo Bioworks (DNA). Company Calendar Today2/08/2025Next Earnings (Estimated)3/27/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KTTA CUSIPN/A CIK1841330 Webwww.pasithea.com Phone702-514-4174FaxN/AEmployees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-15,960,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-81.57% Return on Assets-74.31% Debt Debt-to-Equity RatioN/A Current Ratio14.82 Quick Ratio14.82 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$22.46 per share Price / Book0.09Miscellaneous Outstanding Shares1,270,000Free Float1,060,000Market Cap$2.43 million OptionableNot Optionable Beta0.65 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:KTTA) was last updated on 2/8/2025 by MarketBeat.com Staff From Our PartnersA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredCould 1 of these 5 “America First” stocks 26x from here?Tim Bohen says these 5 tiny “America First” stocks are next up in 2025. They’re trading for less than $2 ri...Timothy Sykes | SponsoredElon Musk’s secret rendezvous with Jensen HuangElon Musk is the world's richest person, and it's not even close. Now he's got the ear of President Trump, ...Weiss Ratings | SponsoredWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nic...Behind the Markets | Sponsored“The most important AI company Americans know least about…”If you own a smartphone, there’s a good chance you’re already benefiting from its technology—because it’s on h...The Oxford Club | SponsoredTrump’s “Shock and Awe” Executive OrderPresident Trump has already launched a "shock and awe" flurry of new Executive Orders... He's withdrawn fro...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pasithea Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pasithea Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.